Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-113581
Filing Date
2025-09-08
Accepted
2025-09-08 16:39:40
Documents
1
Period of Report
2025-09-04

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 10429
  Complete submission text file 0000950170-25-113581.txt   12076
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Issuer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 22722 29TH DR SE SUITE 100 BOTHELL WA 98021
Business Address
Xinos Jaime (Reporting) CIK: 0002041627 (see all company filings)

Type: 4 | Act: 34 | File No.: 033-80623 | Film No.: 251300539